Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to
improve cardiac function in patients with heart failure with a reduced ejection fraction. Its …

Background Serelaxin is a recombinant form of human relaxin-2, a vasodilator hormone that
contributes to cardiovascular and renal adaptations during pregnancy. Previous studies …

Background Lung ultrasound (LUS) has emerged as a new tool for the evaluation of congestion
in heart failure (HF); incorporation of LUS during follow-up may detect congestion earlier …

Background In patients with an acute coronary syndrome (ACS), no conclusive agreement
has been reached to date regarding the association between the different types of atrial …

Aims Systemic venous congestion is associated with an increased risk of acute kidney injury
(AKI) in critically ill patients. Venous Excess Ultrasound Score (VExUS) has been proposed …

Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv
mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in …

BACKGROUND: ST-segment–elevation myocardial infarction (STEMI) guidelines recommend
pharmaco-invasive treatment if timely primary percutaneous coronary intervention (PCI) is …

In the coronavirus disease 2019 (COVID-19) era, the presence of acute respiratory failure is
generally associated with acute respiratory distress syndrome; however, it is essential to …

Background A low proportion of patients with ST-elevation myocardial infarction (STEMI) in
low- to middle-income countries receive reperfusion therapy. Although primary percutaneous …

Background Women with heart failure with reduced ejection fraction (HFrEF) receive less
guideline-recommended therapy and experience worse quality of life than men. Objectives The …